Portola Pharmaceuticals, Inc.
270 East Grand Avenue
South San Francisco
Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.
September 2, 2003
Founder: Charles Homcy and David Philips
CEO: William Lis
CFO: Mardi Dier
CTO: R. Andrew Ramelmeier
Please click here for Portola job opportunities.
Please click here for clinical trial information.